Insider Selling: Heartflow (NASDAQ:HTFL) CFO Sells $190,649.05 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 3,587 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $53.15, for a total value of $190,649.05. Following the completion of the sale, the chief financial officer directly owned 149,587 shares of the company’s stock, valued at $7,950,549.05. This represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vikram Verghese also recently made the following trade(s):

• On Friday, September 18th, Vikram Verghese sold 16,766 shares of Heartflow stock. The stock was sold at an average price of $50.75, for a total transaction of $850,874.50.
• On Thursday, September 17th, Vikram Verghese sold 7,579 shares of Heartflow stock. The stock was sold at an average price of $50.11, for a total transaction of $379,783.69.
• On Tuesday, September 15th, Vikram Verghese sold 668 shares of Heartflow stock. The stock was sold at an average price of $50.01, for a total transaction of $33,406.68.
• On Monday, September 14th, Vikram Verghese sold 4,593 shares of Heartflow stock. The shares were sold at an average price of $50.24, for a total transaction of $230,752.32.
• On Friday, September 11th, Vikram Verghese sold 29,714 shares of Heartflow stock. The shares were sold at an average price of $50.06, for a total transaction of $1,487,482.84.
• On Tuesday, September 8th, Vikram Verghese sold 6,640 shares of Heartflow stock. The shares were sold at an average price of $50.03, for a total transaction of $332,199.20.
• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The stock was sold at an average price of $50.60, for a total transaction of $297,325.60.

Heartflow Stock Performance

NASDAQ:HTFL opened at $59.92 on Friday. The firm’s 50-day moving average is $51.93 and its 200-day moving average is $35.14. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $60.65.

Heartflow (NASDAQ:HTFL) last released its earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business had revenue of $72.86 million during the quarter. During the same quarter in the previous year, the business posted ($0.27) EPS. Sell-side analysts forecast that Heartflow, Inc. will post -0.75 earnings per share for the current year.

Top Heartflow Stories

Investors following HTFL have been watching these stories:

• Positive Sentiment: HeartFlow raised its 2026 revenue guidance to $262 million–$264 million, above the roughly $248.6 million consensus estimate, signaling stronger expected growth. 2026 revenue guidance
• Neutral Sentiment: The CFO’s reported share sale was made under a pre-arranged trading plan to cover tax withholding on vested equity awards, making it a less clear signal about his view of the company. CFO share sale report
• Negative Sentiment: Despite the improvement, HeartFlow still posted a quarterly loss and continues to have a negative net margin, so sustained growth and progress toward profitability remain important risks for investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HTFL shares. Benchmark reissued a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Wall Street Zen cut Heartflow from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Stifel Nicolaus upped their target price on Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Heartflow in a research report on Wednesday, November 4th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $64.00 target price (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Heartflow currently has an average rating of “Moderate Buy” and a consensus price target of $48.62.

Institutional Trading of Heartflow

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XXEC Inc. bought a new position in Heartflow during the second quarter worth about $2,524,764,000. BlackRock Inc. bought a new stake in shares of Heartflow in the 2nd quarter valued at approximately $152,502,000. Bamco Inc. NY bought a new stake in shares of Heartflow in the 2nd quarter valued at approximately $94,625,000. Jupiter Topco LLC acquired a new position in shares of Heartflow in the 2nd quarter worth approximately $70,983,000. Finally, Janus Henderson Group PLC raised its holdings in shares of Heartflow by 152.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after buying an additional 1,315,416 shares in the last quarter.

About Heartflow

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.